RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug targets Hard-to-Treat lymphoma in early trial
Disease control OngoingThis early-phase trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not improved after standard treatments. The drug is a monoclonal antibody designed to help the immune system fight cancer. The main goals are to find the …
Matched conditions: RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:25 UTC
-
Cancer-killing virus plus immune booster shows promise for rare skin tumors
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard care. First, patients receive a virus-based therapy (talimogene laherparepvec) that infects and kills tumor cells. Then, they also get an immunotherapy …
Matched conditions: RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC